From Concept to Market: The Seven-Phase Pathway Medical Device Startups Can Use to Sequence Development and Secure Funding

Taking a medical device from concept to market is less a linear sprint than a chain of dependent decisions—and the most common strategic error is working on the wrong task at the wrong time. Research published in BMC Health Services Research by Mu-Hsun Tseng, Jian-Yu Lian, An-Shun Liu, and Peng-Ting Chen offers founders a way out of that trap: a structured, seven-phase strategic pathway built from 18 critical development factors, with Clinical Needs Assessment identified as the root driver of everything that follows.

The direct answer for founders is this: validate the clinical need first, plan clinical and regulatory strategy second, establish market feasibility and a business model third, and only then move through technology implementation, production, supply chain, and intellectual property protection in sequence. Prioritizing in that order, rather than jumping straight to prototyping, is what the model suggests keeps resource allocation aligned with genuine dependencies.

Navigating the Medical Device Startup Journey: A Seven-Phase Strategic Pathway

The Tseng-led study used two established modeling methods together: interpretive structural modeling (ISM), which organized 18 medical device innovation program factors into seven hierarchical levels, and DEMATEL, which clarified the directional relationships among interacting factors within each level. The result is a pathway that maps what the authors describe as a complex innovation landscape into sequential phases required to translate medical concepts into clinical practice.

The model's value is its ordering logic. It clarifies the relative ordering and causal dependencies among development criteria—foundational steps support downstream execution, so a weak early decision compounds into later failures. The pathway is derived from expert assessments, however, not a universally prescriptive roadmap; it represents one methodology for strategic planning, and regulatory pathways it informs are illustrative rather than specific to any single jurisdiction.

That caveat matters little for its practical use. As Bioengineer.org's reporting on the study notes, startups routinely encounter multifaceted barriers at every stage, from early scientific investigation to formal market entry. A dependency map gives founders a shared language for sequencing decisions—and a defensible narrative for investors.

Phase 1: Foundational Clinical Needs Assessment

The research places Clinical Needs Assessment at the root of the entire hierarchy: every other factor ultimately depends on it. The practical work is confirming whether a clear clinical need exists, typically through conversations with frontline clinicians, direct observation of care settings, and literature review—what BE Health Ventures, a medical-focused venture and accelerator firm, describes as clarifying "Unmet Needs."

The venture firm's warning is blunt: many innovations exhibit technical brilliance but lack support from real clinical pain points, and as a result fail to enter the market. That failure mode explains why the model refuses to let founders begin elsewhere. A validated need anchors the value proposition—evidence that the device addresses a significant unmet clinical problem, demonstrates improved outcomes, or delivers cost savings or efficiency.

Phase 2: Clinical and Regulatory Planning

With a validated need in place, the pathway moves to clinical and regulatory planning. This means determining the device's classification—which in markets like the United States drives whether a product follows a simplified route such as 510(k) or requires full clinical evaluation and premarket approval—and planning the clinical evidence needed to support efficacy and safety claims.

Compliance should be treated as a design input, not an afterthought. Writing for Brightpath Associates, Harrison Shafran argues that startups must align innovative products with compliance from the onset to prevent costly delays in market entry, and that a well-thought-out regulatory strategy enhances credibility with potential investors and partners.

Lynne Lowry, senior vice president of business development at the contract design firm StarFish Medical, makes the same point from an exit perspective: startups should understand the regulatory pathway for their device and engage with regulatory agencies early, because compliance is crucial for both market approval and eventual acquisition. Robust clinical validation, she adds, generates the evidence that is critical for attracting investors and acquirers.

Phase 3: Market Feasibility and Business Model Development

The third phase pairs market feasibility with business model development: assessing whether a commercially viable market exists and constructing the model that connects the device to it. This is where the validated clinical need translates into a fundable proposition—identifying suitable markets, sizing realistic adoption, and defining how the company will generate returns.

Lowry's guidance reinforces the sequencing: founders should identify the most suitable markets and establish a clear market entry plan, considering global expansion possibilities, and plan the desired exit strategy—acquisition, going public, or another option—from the start rather than at the end. Funders, in other words, evaluate Phase 3 output long before Phase 7 work is complete.

The Seven-Phase Strategic Pathway for Medical Device Startups

The following roadmap organizes the seven hierarchical levels identified in the BMC Health Services Research study into a chronological, dependency-based sequence, pairing each level with the practical milestones described by venture and industry sources. Founders can use it to check that critical tasks are being addressed in the correct order and to avoid costly out-of-sequence spending.

Read top to bottom, the table shows the reasoning path the research model establishes: the clinical need drives regulatory and clinical planning, which shapes market and business decisions, which in turn frame technology, production, and supply-chain execution, culminating in IP protection that converts the whole chain into defensible company value. Skipping or weakening an earlier row risks rework in every row below it.

Phase 4-7: Technology Implementation to Intellectual Property Protection

The later phases are where most founders instinctively start—but the model positions them as downstream consequences of earlier choices. Technology implementation means developing a prototype against requirements set by the clinical need, the regulatory pathway, and the business model, not in isolation from them. Production assessment and supply chain planning then determine whether the device can be made and delivered at a cost the business model supports.

Intellectual property protection completes the pathway. Lowry recommends securing strong protection through patents and trademarks to create a barrier to entry for competitors, and a strong IP portfolio is widely treated as crucial for company valuation—particularly for startups whose realistic exit is acquisition by a larger device company.

Critical Business and Operational Factors for Success

The pathway organizes the development sequence, but commercial success—and a successful exit—depends on factors that run across all seven phases. Lowry's list of 18 business factors she believes are most important to a successful exit includes several that founders should treat as parallel workstreams: developing a strong value proposition, building a strong team with expertise in device development, regulatory affairs, and sales and marketing, and engaging professional legal, financial, product development, and M&A advisors.

Attracting investment, she argues, should target investors and strategic partners who provide not only capital but industry expertise and connections. Shafran adds that strategic partnerships with established healthcare ecosystem players provide resources, insights, and networks for product development and commercialization, and that collaboration with healthcare professionals and institutions supplies the clinical data needed to iterate effectively.

Two cautions temper the framework. The specific criteria for success vary with stakeholder goals, as Lowry notes—each startup journey is unique, and strategy must adapt to changing market conditions. And the pathway itself, derived from expert assessment using ISM-DEMATEL, is a structured analytical modeling construct: a planning instrument, not a guarantee.

Optimizing Your Medical Device Development Journey

Medical device startups should adopt a structured, phase-based approach, prioritizing foundational clinical needs assessment and integrating business and regulatory strategies early to navigate development efficiently and attract funding. The measure of progress is concrete: successful progression through each of the seven strategic phases, marked by validated clinical needs, established regulatory pathways, and secured intellectual property, indicating readiness for subsequent investment rounds or market entry. Founders who can demonstrate that sequence to investors—with each phase's evidence in hand—have turned a research-derived hierarchy into a working funding narrative.

Sources

• An ISM-DEMATEL approach for developing a structured strategic pathway in medical device innovation — SpringerLink
• New Strategic Modeling Pathway Maps Priority Stages for Medical Device — BIOENGINEER.ORG
• Key Milestones in Medical Device Product Development - BE Health Ventures — 比翼生醫
• Launching a Medical Device Startup: Key Considerations - Brightpath Associates
• 18 Business Factors That Determine Successful Medical Device Exits — StarFish Medical